Raising the bar for gene patents  by Bonetta, Laura
With the recent completion of a
working draft of the human genome
sequence, attention is turning once
again to the controversial issue of gene
patenting.  In response to mounting
criticism about the ease with which
some groups have been able to apply
for and receive patents on poorly
characterized human gene sequences,
the US Patent and Trademark Office
(USPTO) has recently released new
guidelines that will affect the outcome
of gene patent applications. 
In order for a gene patent to be
approved, a patent will have to not
only provide an adequate description
of a gene, but also link the gene with
a specific, useful application. With
the new guidelines, the USPTO
again rejected all arguments against
the patenting of genes. “The
eligibility of genes to be patented is
firmly based in legislative history and
judicial law,” explains John Doll,
director of biotechnology at USPTO.
In the United States, a patent
application directed to a genetic
sequence has several hurdles to
overcome: it has to be novel (for
example, a genetic sequence that has
not been previously published), not
obvious to people working in the
field, and useful. This final
requirement — utility — is the
central focus of the new guidelines.
While it is clear that the description
of a human gene encoding a
medically useful protein is
patentable whereas raw DNA
sequence data are not, the new
guidelines provide a framework for
determining where to draw the line
between the two extremes.
Patent applicants must be able to
show specific, credible, and
substantial utility for gene
sequences. Specific utility means
that the applicant has to know what
the sequence does. Credible utility
means that the claim must be
believable to people who know the
field. Lastly, the substantial utility
criterion, which was introduced with
the new guidelines, states that the
sequence must have a ‘real-world’
use — in other words, there has to be
a clearly defined use for it in
commerce. 
Patent applicants must show
specific, credible, and substantial
utility for gene sequences
For example, an expressed sequence
tag (EST) can be patented if it
provides the basis for a diagnostic
test. On the other hand, the
argument that an EST is useful
because it can allow scientists to find
the entire gene and is thus a tool for
further research is unlikely to meet
the utility requirement. The scope of
an EST patent would also be limited
to the sequence included within the
EST and not the sequence
surrounding it (for example, an entire
gene if the EST happens to fall
within a gene).
‘Gene patents’ is a broad term
that covers patenting of genetic
sequences and the processes for
isolating them. From 1997 to 1999,
more than 9,000 gene-related patents
were issued by the USPTO (see
Figure), about one third of those in
1999 alone. The US biotechnology
company Incyte Genomics (Palo
Alto, California) tops the list among
gene patent holders with over 500
gene-related patents in the United
States. The company says it has filed
patent applications covering portions
of more than 50,000 genes, including
7,000 that are full length. While
Celera Genomics (Rockville,
Maryland), the company lead by
J. Craig Venter that recently released
its assembly of the human genome
sequence, has filed provisional
patent applications on at least 6,500
gene sequences, the company has
yet to be awarded any human gene
patents. But the rush to patent
human genes is not confined to the
biotechnology and pharmaceutical
industries. Universities and
government agencies are also
involved in the race to patent genes;
the University of California and the
National Institutes of Health are the
two most active.
According to Lila Feisee, director
of intellectual property for the
Biotechnology Industry Organization
(BIO), members of the
biotechnology industry generally
approve of the new USPTO
guidelines. Critics, however, believe
that the bar is still not high enough.
For example, critics from the NIH
have said that computer homology
studies of gene sequences are not
sufficient for determining gene
function and that the new standards
should not allow claims of ‘predicted’
function. The USPTO position,
however, is that, under US law, a
utility must be credible but does not
have to be proven to an absolute
certainty. According to the new
guidelines, “when a patent
application claiming a nucleic acid
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asserts a specific, substantial, and
credible utility, and bases the
assertion upon homology to existing
nucleic acids or proteins having an
accepted utility, the asserted utility
must be accepted by the examiner
unless the Office has sufficient
evidence or sound scientific
reasoning to rebut such an assertion.” 
The entire concept that genes
should be patented has been the
subject of heated debate. When the
USPTO originally proposed the
utility guidelines in December 1999,
it received several comments from
the public arguing against the notion
of awarding patents for genetic
materials based on the premise that
genes are part of nature and not an
invention. Such arguments were
rejected by the USPTO on the
grounds that DNA fragments that are
isolated, cloned, and purified are,
from the perspective of patent law,
just another man-made invention.
The practice of patenting pieces of
nature is not new. Indeed, according
to the USPTO, Louis Pasteur
received US Patent 141,072 in 1873,
claiming “yeast, free from organic
germs of disease as an article of
manufacture.”
Another criticism of gene patents
focuses on concerns that they will
stifle laboratory research. A gene
patent entitles the owner to 20-year
patent protection from others
working on the same gene. Some
scientists argue that current patent
law discourages scientists from
developing diagnostic tests using
genes that have been patented for
fear of being shut down. The
USPTO addressed these concerns
by saying that “it is somewhat rare
for academic researchers to be
sued by commercial patent owners
for patent infringement. Most
inventions are made available to
academic researchers on very
favorable licensing terms, which
enable them to continue their
research.” 
John F. Merz, an assistant
professor of bioethics at the
University of Pennsylvania,
disagrees. “Myriad Genetics [the
company that holds patents to the
breast cancer genes BRCA1 and
BRCA2] narrowly defined what they
considered to fall outside of the
ambit of patent protection: funded,
hypothesis-driven research wherein
no results of testing would be
provided to patients/subjects. So, did
they stop doctors from doing studies?
I have no doubt,” he says. Michael
Watson, a professor of pediatrics at
Washington University in St. Louis
concurs. According to Watson, “while
basic research is protected, the
clinical investigative stage during
which the analytical and clinical
performance characteristics of tests
are determined (and which may take
many years) is directly impacted.”
Another concern is that as the
number of genes receiving patents
grows, genetic testing of patients will
become prohibitively expensive, with
physicians having to pay a royalty for
every genetic test performed.
Biotechnology companies counter by
suggesting that without patent
protection, research and development
costs will not be recouped and there
will be little incentive for
investments within the
biotechnology industry. Furthermore,
representatives from biotechnology
companies will point out that many
companies will offer favorable
licensing terms to physicians. 
A recent example is a deal that
was struck between the UK’s
National Health Service (NHS) and
Rosgen, the biotechnology company
that holds exclusive license to
market Myriad’s genetic tests for
breast cancer in the UK. The
company, based at the Roslin campus
where Dolly the sheep was cloned,
agreed that there would be no royalty
charges for tests performed by the
NHS. The company, however, plans
to charge private patients from £450
($700) per test.
The debate over gene patents is
unlikely to end anytime soon.
Watson, who helped draft a
resolution endorsed by the
American College of Genetics
calling for an end to human gene
patenting, is pushing for strong
action from congressional and other
federal oversight bodies. In 1996,
pressure from physicians and patient
groups resulted in Congress passing
a law, the ‘Ganske legislation’,
which holds physicians and medical
institutions free of liability for
infringing patents on medical
processes. Watson thinks the
legislation should now be extended
to genetic testing. “This allows the
patent protection for future
development to remain, while
protecting the practitioner from
liability for [infringement].”
Laura Bonetta is a freelance science writer
based in the Washington DC area.
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Number of DNA and RNA patents issued by
USPTO per year. These numbers include DNA
and RNA sequences of plants, animals and
humans, including full-length genes and gene
fragments (which in turn include single-
nucleotide polymorphisms (SNPs) and ESTs).
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